{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:11:53Z","timestamp":1791277913255,"version":"4.1.0"},"reference-count":140,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In patients with chronic myeloid leukemia (CML) in chronic phase who have achieved complete molecular remission on imatinib therapy, clinical trials from France and Australia have demonstrated that the majority experience prompt molecular relapse of their leukemia upon discontinuation of the drug, showing that long-term monotherapy with tyrosine kinase inhibitors is not curative in the majority of patients with CML. This has focused attention on strategies to eradicate residual disease in CML that is presumed to arise from malignant Ph+ stem cells, which should result in permanent cure and long-term leukemia-free survival. Here, we review the evidence that targeting CML stem cells will be of clinical benefit and discuss pharmacological and immunological approaches to accomplish this goal. Where possible, we link preclinical studies of CML stem cell biology to emerging results from clinical trials of agents that may target these cells.<\/jats:p>","DOI":"10.1182\/asheducation-2013.1.189","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T15:51:13Z","timestamp":1386345073000},"page":"189-200","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond"],"prefix":"10.1182","volume":"2013","author":[{"given":"Wesam","family":"Ahmed","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology and Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Van Etten","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology and Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA; and"},{"name":"Division of Hematology\/Oncology and Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"18","key":"2019111703382669400_B1","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","article-title":"Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008","volume":"29","author":"Bjorkholm","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111703382669400_B2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2019111703382669400_B3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2012.0184","article-title":"Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure","volume":"10","author":"Cortes","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"2019111703382669400_B4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/asheducation-2011.1.136","article-title":"Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?","volume":"2011","author":"Melo","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"14","key":"2019111703382669400_B5","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111703382669400_B6","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.6004\/jnccn.2009.0069","article-title":"Issues of imatinib and pregnancy outcome","volume":"7","author":"Apperley","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"issue":"22","key":"2019111703382669400_B7","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"Experts in chronic myeloid leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts","volume":"121","author":"Kantarjian","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2019111703382669400_B8","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"issue":"9","key":"2019111703382669400_B9","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"2019111703382669400_B10","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111703382669400_B11","first-page":"3771","article-title":"Early switch to nilotinib does not overcome the adverse outcome for CML patients failing to achieve early molecular response on imatinib, despite excellent overall outcomes in the TIDEL II trial [abstract]","volume":"120","author":"Yeung","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"6","key":"2019111703382669400_B12","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.stem.2012.05.007","article-title":"Cancer stem cells: current status and evolving complexities","volume":"10","author":"Visvader","year":"2012","journal-title":"Cell Stem Cell"},{"issue":"7222","key":"2019111703382669400_B13","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nature07567","article-title":"Efficient tumour formation by single human melanoma cells","volume":"456","author":"Quintana","year":"2008","journal-title":"Nature"},{"issue":"5836","key":"2019111703382669400_B14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1126\/science.1142596","article-title":"Tumor growth need not be driven by rare cancer stem cells","volume":"317","author":"Kelly","year":"2007","journal-title":"Science"},{"issue":"6","key":"2019111703382669400_B15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ccr.2004.10.015","article-title":"MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors","volume":"6","author":"Huntly","year":"2004","journal-title":"Cancer Cell"},{"key":"2019111703382669400_B16","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1182\/blood.V87.4.1539.bloodjournal8741539","article-title":"Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis","volume":"87","author":"Sirard","year":"1996","journal-title":"Blood"},{"key":"2019111703382669400_B17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood.V91.2.630","article-title":"Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD\/SCID mice using blood-derived mononuclear or CD34+ cells","volume":"91","author":"Lewis","year":"1998","journal-title":"Blood"},{"key":"2019111703382669400_B18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med"},{"issue":"45","key":"2019111703382669400_B19","doi-asserted-by":"crossref","first-page":"16870","DOI":"10.1073\/pnas.0606509103","article-title":"Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice","volume":"103","author":"Hu","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"2019111703382669400_B20","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1182\/blood-2009-04-215376","article-title":"BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells","volume":"115","author":"Schemionek","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111703382669400_B21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"12","key":"2019111703382669400_B22","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"issue":"11","key":"2019111703382669400_B23","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111703382669400_B24","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/sj.leu.2405086","article-title":"Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors","volume":"22","author":"Konig","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"2019111703382669400_B25","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"issue":"2","key":"2019111703382669400_B26","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2010-08-303495","article-title":"Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib","volume":"119","author":"Kumari","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2019111703382669400_B27","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/blood-2011-12-396226","article-title":"BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia","volume":"119","author":"Chomel","year":"2012","journal-title":"Blood"},{"issue":"7046","key":"2019111703382669400_B28","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"},{"issue":"10","key":"2019111703382669400_B29","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","article-title":"Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications","volume":"12","author":"Roeder","year":"2006","journal-title":"Nat Med"},{"issue":"6","key":"2019111703382669400_B30","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1182\/blood-2011-02-339267","article-title":"Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells","volume":"118","author":"Tang","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019111703382669400_B31","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-11-0396","article-title":"BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment","volume":"17","author":"Stein","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2019111703382669400_B32","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019111703382669400_B33","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111703382669400_B34","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"issue":"21","key":"2019111703382669400_B35","first-page":"916","article-title":"Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)-chronic myeloid leukemia (CML) patients with stable undetectable BCR-ABL transcripts [abstract]","volume":"120","author":"Rea","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"10","key":"2019111703382669400_B36","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2005-08-3320","article-title":"Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy","volume":"107","author":"Kaeda","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111703382669400_B37","first-page":"513","article-title":"Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"issue":"4","key":"2019111703382669400_B38","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"issue":"21","key":"2019111703382669400_B39","first-page":"2299","article-title":"Interferon alpha alone Is able to cure chronic myeloid leukemia In a small subset of patients despite the persistence of leukemic cells: experience of long follow up after treatment discontinuation [abstract]","volume":"116","author":"Mahon","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"8","key":"2019111703382669400_B40","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"O'Hare","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2019111703382669400_B41","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/bph.12183","article-title":"Targeting Survival Pathways in Chronic Myeloid Leukaemia Stem Cells","volume":"169","author":"Sinclair","year":"2013","journal-title":"Br J Pharmacol"},{"issue":"1","key":"2019111703382669400_B42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11899-012-0150-1","article-title":"Signal transduction in the chronic leukemias: implications for targeted therapies","volume":"8","author":"Ahmed","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"issue":"49","key":"2019111703382669400_B43","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","article-title":"P210 and P190BCR\/ABL induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members","volume":"271","author":"Ilaria","year":"1996","journal-title":"J Biol Chem"},{"issue":"43","key":"2019111703382669400_B44","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1038\/sj.onc.1204834","article-title":"Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation","volume":"20","author":"Xie","year":"2001","journal-title":"Oncogene"},{"issue":"3","key":"2019111703382669400_B45","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/leu.2010.287","article-title":"Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia","volume":"25","author":"Samanta","year":"2011","journal-title":"Leukemia"},{"issue":"6","key":"2019111703382669400_B46","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2003-01-0062","article-title":"Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development","volume":"102","author":"Wertheim","year":"2003","journal-title":"Blood"},{"issue":"3","key":"2019111703382669400_B47","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nchembio.775","article-title":"BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia","volume":"8","author":"Hantschel","year":"2012","journal-title":"Nat Chem Biol"},{"issue":"14","key":"2019111703382669400_B48","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/onc.2009.7","article-title":"Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients","volume":"28","author":"Samanta","year":"2009","journal-title":"Oncogene"},{"issue":"6","key":"2019111703382669400_B49","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jnci\/djt006","article-title":"Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1-BCR-ABL-JAK2 Complex","volume":"105","author":"Chen","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2019111703382669400_B50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ccr.2004.12.010","article-title":"Stat5 tetramer formation is associated with leukemogenesis","volume":"7","author":"Moriggl","year":"2005","journal-title":"Cancer Cell"},{"issue":"3","key":"2019111703382669400_B51","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia","volume":"2","author":"Hoelbl","year":"2010","journal-title":"EMBO Mol Med"},{"issue":"15","key":"2019111703382669400_B52","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1182\/blood-2011-12-397554","article-title":"Essential role for Stat5a\/b in myeloproliferative neoplasms induced by BCR-ABL1 and Jak2V617F in mice","volume":"119","author":"Walz","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2019111703382669400_B53","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-12-3955","article-title":"Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem\/progenitor cells","volume":"73","author":"Casetti","year":"2013","journal-title":"Cancer Res"},{"issue":"12","key":"2019111703382669400_B54","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","article-title":"The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors","volume":"117","author":"Nelson","year":"2011","journal-title":"Blood"},{"key":"2019111703382669400_B55","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","article-title":"Essential role for Gab2 in transformation by BCR\/ABL","volume":"1","author":"Sattler","year":"2002","journal-title":"Cancer Cell"},{"issue":"7281","key":"2019111703382669400_B56","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"issue":"11","key":"2019111703382669400_B57","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.20110304","article-title":"BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia","volume":"208","author":"Hurtz","year":"2011","journal-title":"J Exp Med"},{"issue":"15","key":"2019111703382669400_B58","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/blood-2008-07-168773","article-title":"A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo","volume":"113","author":"Cerchietti","year":"2009","journal-title":"Blood"},{"key":"2019111703382669400_B59","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1073\/pnas.0400063101","article-title":"Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs","volume":"101","author":"Mohi","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2019111703382669400_B60","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm.2091","article-title":"Effective and selective targeting of leukemia cells using a TORC1\/2 kinase inhibitor","volume":"16","author":"Janes","year":"2010","journal-title":"Nat Med"},{"issue":"28","key":"2019111703382669400_B61","doi-asserted-by":"crossref","first-page":"12469","DOI":"10.1073\/pnas.1005114107","article-title":"Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells","volume":"107","author":"Carayol","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"2019111703382669400_B62","doi-asserted-by":"crossref","first-page":"6399","DOI":"10.1182\/blood-2011-01-332783","article-title":"Antileukemic effects of AMPK activators on BCR-ABL-expressing cells","volume":"118","author":"Vakana","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111703382669400_B63","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1158\/0008-5472.CAN-09-3537","article-title":"Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62\/SQSTM1 expression and AMPK activation","volume":"70","author":"Puissant","year":"2010","journal-title":"Cancer Res"},{"issue":"5","key":"2019111703382669400_B64","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.exphem.2013.02.001","article-title":"Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia","volume":"41","author":"Stoklosa","year":"2013","journal-title":"Exp Hematol"},{"issue":"8","key":"2019111703382669400_B65","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2019111703382669400_B66","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1073\/pnas.0900189106","article-title":"Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation","volume":"106","author":"Abrahamsson","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2019111703382669400_B67","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"issue":"1","key":"2019111703382669400_B68","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/leu.2008.262","article-title":"beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia","volume":"23","author":"Hu","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"2019111703382669400_B69","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.stem.2012.02.017","article-title":"Genetic and pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML","volume":"10","author":"Heidel","year":"2012","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2019111703382669400_B70","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2007-07-099754","article-title":"Simultaneous loss of beta- and gamma-catenin does not perturb hematopoiesis or lymphopoiesis","volume":"111","author":"Koch","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111703382669400_B71","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.canlet.2011.08.002","article-title":"Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65\u2013a novel Wnt\/beta-catenin signaling inhibitor","volume":"312","author":"Nagao","year":"2011","journal-title":"Cancer Lett"},{"issue":"21","key":"2019111703382669400_B72","first-page":"65","article-title":"Treatment with \u03b2-Catenin antagonist BC2059 exerts single agent efficacy and exerts improved activity with tyrosine kinase inhibitor (TKI) or pan-histone deacetylase (HDAC) inhibitor against human CML and myeloproliferative neoplasm (MPN) progenitor cells [abstract]","volume":"118","author":"Fiskus","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"6","key":"2019111703382669400_B73","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.cell.2009.01.015","article-title":"Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration","volume":"136","author":"Goessling","year":"2009","journal-title":"Cell"},{"issue":"10","key":"2019111703382669400_B74","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood-2011-06-361261","article-title":"Targeting of GSK3beta promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells","volume":"119","author":"Reddiconto","year":"2012","journal-title":"Blood"},{"issue":"17","key":"2019111703382669400_B75","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.4161\/cc.9.17.12945","article-title":"Hedgehog pathway activation in chronic myeloid leukemia","volume":"9","author":"Jagani","year":"2010","journal-title":"Cell Cycle"},{"issue":"3","key":"2019111703382669400_B76","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"issue":"21","key":"2019111703382669400_B77","first-page":"514","article-title":"Inhibition of chronic myeloid leukemia stem cells by the combination of the Hedgehog pathway inhibitor LDE225 with nilotinib [abstract]","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111703382669400_B78","first-page":"531","article-title":"Targeting the Hedgehog signaling pathway limits the self-renewal of BCR-ABL1 positive leukemia cells: molecular mechanisms [abstract]","volume":"120","author":"Tauchi","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111703382669400_B79","first-page":"424","article-title":"Phase 1 dose-escalation study of PF-04449913, an oral hedgehog (Hh) inhibitor, in patients with select hematologic malignancies [abstract]","volume":"118","author":"Jamieson","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"11","key":"2019111703382669400_B80","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0145-2126(95)00043-7","article-title":"Selective inhibitors of 5-lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apoptosis","volume":"19","author":"Anderson","year":"1995","journal-title":"Leuk Res"},{"issue":"7","key":"2019111703382669400_B81","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/ng.389","article-title":"Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia","volume":"41","author":"Chen","year":"2009","journal-title":"Nat Genet"},{"issue":"12","key":"2019111703382669400_B82","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1182\/blood-2007-11-126003","article-title":"Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data","volume":"111","author":"Hassane","year":"2008","journal-title":"Blood"},{"issue":"26","key":"2019111703382669400_B83","doi-asserted-by":"crossref","first-page":"6909","DOI":"10.1182\/blood-2010-11-317750","article-title":"Delta12-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells in mice","volume":"118","author":"Hegde","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2019111703382669400_B84","first-page":"355","article-title":"The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome","volume":"11","author":"An","year":"2000","journal-title":"Cell Growth Differ"},{"issue":"5","key":"2019111703382669400_B85","first-page":"1799","article-title":"Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts","volume":"61","author":"Nimmanapalli","year":"2001","journal-title":"Cancer Res"},{"issue":"8","key":"2019111703382669400_B86","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2002-05-1361","article-title":"BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90","volume":"100","author":"Gorre","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2019111703382669400_B87","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2006-10-054098","article-title":"Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells","volume":"110","author":"Peng","year":"2007","journal-title":"Blood"},{"key":"2019111703382669400_B88","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1038\/cddis.2011.122","article-title":"Role of the promyelocytic leukaemia protein in cell death regulation","volume":"3","author":"Salomoni","year":"2012","journal-title":"Cell Death Dis"},{"issue":"7198","key":"2019111703382669400_B89","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/nature07016","article-title":"PML targeting eradicates quiescent leukaemia-initiating cells","volume":"453","author":"Ito","year":"2008","journal-title":"Nature"},{"issue":"9","key":"2019111703382669400_B90","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1073\/pnas.0813142106","article-title":"A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR\/ABL-associated leukemia","volume":"106","author":"Zhang","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"2019111703382669400_B91","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/blood-2012-01-402578","article-title":"Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide","volume":"120","author":"Goussetis","year":"2012","journal-title":"Blood"},{"issue":"24","key":"2019111703382669400_B92","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-07-1595","article-title":"The roles of therapy-induced autophagy and necrosis in cancer treatment","volume":"13","author":"Amaravadi","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111703382669400_B93","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J Clin Invest"},{"issue":"1","key":"2019111703382669400_B94","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3109\/10428194.2012.698737","article-title":"Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy","volume":"54","author":"Schafranek","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2019111703382669400_B95","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3109\/10428194.2012.656105","article-title":"Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia","volume":"53","author":"Carella","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2019111703382669400_B96","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2002-08-2675","article-title":"Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells","volume":"101","author":"Nimmanapalli","year":"2003","journal-title":"Blood"},{"issue":"16","key":"2019111703382669400_B97","first-page":"5126","article-title":"Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells","volume":"63","author":"Nimmanapalli","year":"2003","journal-title":"Cancer Res"},{"issue":"1","key":"2019111703382669400_B98","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1600-0609.2009.01242.x","article-title":"Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro","volume":"83","author":"Kircher","year":"2009","journal-title":"Eur J Haematol"},{"issue":"2","key":"2019111703382669400_B99","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1078-0432.CCR-12-2799","article-title":"PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR\/ABL+ leukemia cells in vitro and in vivo","volume":"19","author":"Dasmahapatra","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111703382669400_B100","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"issue":"22","key":"2019111703382669400_B101","first-page":"2194","article-title":"A phase I study of the HDAC Inhibitor LBH589 in combination with imatinib for patients with CML in cytogenetic remission with residual disease detectable by Q-PCR [abstract]","volume":"114","author":"Bhatia","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"8","key":"2019111703382669400_B102","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1182\/blood-2011-06-361691","article-title":"Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis","volume":"119","author":"Yuan","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019111703382669400_B103","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Cell"},{"issue":"3","key":"2019111703382669400_B104","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","article-title":"A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition","volume":"12","author":"Goff","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"5","key":"2019111703382669400_B105","doi-asserted-by":"crossref","first-page":"e5428","DOI":"10.1371\/journal.pone.0005428","article-title":"Altering chemosensitivity by modulating translation elongation","volume":"4","author":"Robert","year":"2009","journal-title":"Plos One"},{"issue":"6","key":"2019111703382669400_B106","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/leu.2011.55","article-title":"Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem\/progenitor cells","volume":"25","author":"Allan","year":"2011","journal-title":"Leukemia"},{"issue":"22","key":"2019111703382669400_B107","doi-asserted-by":"crossref","first-page":"10959","DOI":"10.1158\/0008-5472.CAN-06-1216","article-title":"A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia","volume":"66","author":"Chen","year":"2006","journal-title":"Cancer Res"},{"issue":"9","key":"2019111703382669400_B108","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/cncr.20975","article-title":"Phase I\/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib","volume":"103","author":"Marin","year":"2005","journal-title":"Cancer"},{"issue":"5","key":"2019111703382669400_B109","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3816\/CLML.2010.n.073","article-title":"The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge","volume":"10","author":"Nicolini","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2019111703382669400_B110","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2009.52","article-title":"Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice","volume":"23","author":"Chen","year":"2009","journal-title":"Leukemia"},{"issue":"26","key":"2019111703382669400_B111","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111703382669400_B112","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"issue":"7240","key":"2019111703382669400_B113","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFNalpha activates dormant haematopoietic stem cells in vivo","volume":"458","author":"Essers","year":"2009","journal-title":"Nature"},{"issue":"8","key":"2019111703382669400_B114","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia","volume":"28","author":"Burchert","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111703382669400_B115","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/leu.2012.313","article-title":"Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia","volume":"27","author":"Talpaz","year":"2013","journal-title":"Leukemia"},{"key":"2019111703382669400_B116","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1182\/blood.V87.9.3587.bloodjournal8793587","article-title":"Specific human cellular immunity to bcr-abl oncogene-derived peptides","volume":"87","author":"Bocchia","year":"1996","journal-title":"Blood"},{"issue":"9460","key":"2019111703382669400_B117","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)70931-4","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"issue":"11","key":"2019111703382669400_B118","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/sj.leu.2404858","article-title":"Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study","volume":"21","author":"Rojas","year":"2007","journal-title":"Leukemia"},{"issue":"17","key":"2019111703382669400_B119","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1002\/cncr.24468","article-title":"Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial","volume":"115","author":"Jain","year":"2009","journal-title":"Cancer"},{"issue":"2","key":"2019111703382669400_B120","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2141.2010.08187.x","article-title":"Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance","volume":"150","author":"Breccia","year":"2010","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111703382669400_B121","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nrclinonc.2010.141","article-title":"Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination","volume":"7","author":"Bocchia","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2019111703382669400_B122","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1600-0609.2010.01497.x","article-title":"WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient","volume":"85","author":"Oji","year":"2010","journal-title":"Eur J Haematol"},{"issue":"9","key":"2019111703382669400_B123","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/leu.2008.161","article-title":"Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy","volume":"22","author":"Yong","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"2019111703382669400_B124","doi-asserted-by":"crossref","first-page":"e11770","DOI":"10.1371\/journal.pone.0011770","article-title":"PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal","volume":"5","author":"Kanodia","year":"2010","journal-title":"Plos One"},{"issue":"3","key":"2019111703382669400_B125","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3324\/haematol.2010.031674","article-title":"Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies","volume":"96","author":"Rezvani","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"2019111703382669400_B126","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-09-2046","article-title":"K562\/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate","volume":"16","author":"Smith","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"37","key":"2019111703382669400_B127","doi-asserted-by":"crossref","first-page":"16280","DOI":"10.1073\/pnas.1004408107","article-title":"Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein","volume":"107","author":"Jaras","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"2019111703382669400_B128","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1182\/blood-2012-09-458935","article-title":"Selective killing of candidate AML stem cells by antibody targeting of IL1RAP","volume":"121","author":"Askmyr","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2019111703382669400_B129","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/cyto.b.21066","article-title":"The hematopoietic stem cell niche\u2013home for friend and foe?","volume":"84","author":"Krause","year":"2013","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"2019111703382669400_B130","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1158\/1078-0432.CCR-05-0429","article-title":"Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate","volume":"12","author":"Jorgensen","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019111703382669400_B131","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1158\/0008-5472.CAN-06-2014","article-title":"Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment","volume":"67","author":"Holtz","year":"2007","journal-title":"Cancer Res"},{"issue":"6","key":"2019111703382669400_B132","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/leu.2009.43","article-title":"A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response","volume":"23","author":"Drummond","year":"2009","journal-title":"Leukemia"},{"issue":"5","key":"2019111703382669400_B133","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1158\/1535-7163.MCT-07-2331","article-title":"Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells","volume":"7","author":"Weisberg","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"2019111703382669400_B134","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ccr.2011.05.007","article-title":"Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia","volume":"19","author":"Schmidt","year":"2011","journal-title":"Cancer Cell"},{"issue":"5","key":"2019111703382669400_B135","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/leu.2011.325","article-title":"Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors","volume":"26","author":"Traer","year":"2012","journal-title":"Leukemia"},{"issue":"10","key":"2019111703382669400_B136","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling","volume":"121","author":"Zhang","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019111703382669400_B137","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/leu.2011.360","article-title":"Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib","volume":"26","author":"Weisberg","year":"2012","journal-title":"Leukemia"},{"issue":"13","key":"2019111703382669400_B138","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1182\/blood-2011-05-355396","article-title":"Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML","volume":"120","author":"Agarwal","year":"2012","journal-title":"Blood"},{"key":"2019111703382669400_B139","article-title":"Differential regulation of myeloid leukemias by the bone marrow microenvironment","author":"Krause","journal-title":"Nat Med"},{"issue":"25","key":"2019111703382669400_B140","doi-asserted-by":"crossref","first-page":"E2298","DOI":"10.1073\/pnas.1301838110","article-title":"Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function","volume":"110","author":"Lim","year":"2013","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/189\/1249916\/bep00113000189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/189\/1249916\/bep00113000189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T04:05:53Z","timestamp":1716264353000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2013\/1\/189\/20772\/Alternative-approaches-to-eradicating-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":140,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2013.1.189","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}